

Predictors of CD4⁺ T-Cell Counts of HIV Type 1–Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes

The Pursuing Later Treatment Option II (PLATO II) Project Team of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE)^a

Background. Low CD4⁺ T-cell counts are the main factor leading to clinical progression in human immunodeficiency virus type 1 (HIV-1) infection. We aimed to investigate factors affecting CD4⁺ T-cell counts after triple-class virological failure.

Methods. We included individuals from the COHERE database who started antiretroviral therapy from 1998 onward and who experienced triple-class virological failure. CD4⁺ T-cell counts obtained after triple-class virologic failure were analyzed using generalized estimating equations.

Results. The analyses included 2424 individuals with a total of 23 922 CD4⁺ T-cell count measurements. In adjusted models (excluding current viral load and year), CD4⁺ T-cell counts were higher with regimens that included boosted protease inhibitors (increase, 22 cells/μL [95% confidence interval {CI}, 3.9–41]; $P = .017$) or drugs from the new classes (increase, 39 cells/μL [95% CI, 15–62]; $P = .001$), compared with nonnucleoside reverse-transcriptase inhibitor–based regimens. These associations disappeared when current viral load and/or calendar year were included. Compared with viral levels of $<2.5 \log_{10}$ copies/mL, levels of 2.5–3.5, 3.5–4.5, 4.5–5.5, and $>5.5 \log_{10}$ copies/mL were associated with CD4⁺ T-cell count decreases of 51, 84, 137, and 186 cells/μL, respectively ($P < .001$).

Conclusions. The approximately linear inverse relationship between \log_{10} viral load and CD4⁺ T-cell count indicates that there are likely immunologic benefits from lowering viral load even by modest amounts that do not lead to undetectable viral loads. This is important for patients with low CD4⁺ T-cell counts and few drug options.

Keywords. HIV-1; antiretroviral agents; triple-class virologic failure; CD4 lymphocyte count; HIV cohort study.

The aim of antiretroviral treatment is to suppress viral replication to levels below the limit of detection in standard assays in plasma [1]. However, for some individuals this goal cannot be achieved or, if achieved, cannot be maintained. Although newer drugs in other classes are available, virological failure of the 3 original antiretroviral drug classes, nucleoside reverse-

transcriptase inhibitors (NRTIs), nonnucleoside reverse-transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs)—so called triple-class virologic failure—is a serious concern considering the need for suppression to be maintained for a lifetime [2, 3]. Many people were initially treated with monotherapy, dual therapy, or combination regimens with low potency or had adherence problems. When adherence is particularly low, virological failures often occur without detection of resistance [4]. In people with triple-class virologic failure, particularly in those with emergent resistant virus, it has often been difficult to compose suitably active regimens [5, 6], and the required more complex regimens have posed problems of tolerability and adherence. In most recent years, however, new drugs from novel classes have partially alleviated these concerns [7, 8]. Continued viral

Received 13 July 2012; accepted 27 September 2012.

^aMembers of the PLATO II Project Team and COHERE are listed at the end of the text.

Correspondence: Bruno Ledergerber, PhD, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Rämistrasse 100, CH-8091 Zurich, Switzerland (infled@usz.uzh.ch).

The Journal of Infectious Diseases

© The Author 2012. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

DOI: 10.1093/infdis/jis752

replication and the resulting decrease in CD4⁺ T-cell count are the main factors leading to clinical AIDS-defining diseases and mortality. We have shown in the Pursuing Later Treatment Options (PLATO) collaboration that increases in CD4⁺ T-cell count can be achieved even when virus is not completely suppressed [9]. However, many of the participants in that study started antiretroviral therapy (ART) with a suboptimal monotherapy or dual therapy regimen and virtually had sequential monotherapies for several years, so the relevance for the current ART era is uncertain. The incidence of triple-class virologic failure has been declining, mainly because more people currently receiving treatment started ART as combination therapy (cART) including 2 NRTIs with a NNRTI or a ritonavir-boosted protease inhibitor (PI/r) but also because new and potentially better tolerated drugs have become available [3]. In another study of the PLATO II project, we showed that the probability of achieving viral levels below the limit of detection after triple-class virologic failure increased, from 19.5% in 2000 to 57.9% in 2009 [10]. Nevertheless, because of improved survival, the prevalence of persons with triple-class virologic failure has remained stable [3, 11] or is even increasing [2, 12]. The aim of this study was to investigate which factors affect CD4⁺ T-cell counts after triple-class virologic failure in the current ART era, in which cART is used from the time of initiation of therapy.

METHODS

Patients

COHERE is a collaboration of most HIV observational cohorts in Europe [13]. The 24 cohorts participating in the PLATO II project submitted data in a standardized format [14] (updated versions are available at: <http://www.hicdep.org/>) to one of two regional coordinating centers, where error checks were performed prior to merging the cohort data to form the COHERE database. Individuals appearing in >1 cohort were identified, and duplicate records were removed. This analysis on data merged in 2010 was restricted to ART-naïve persons aged ≥16 years who started ART from 1998 onward and who experienced triple-class virologic failure. Individuals were followed from the start of ART to their last viral load measurement.

Virological failure of a drug was defined as 1 viral load of >500 copies/mL after at least 4 months of continuous use. Triple-class virologic failure was defined as virologic failure of 2 NRTIs, 1 NNRTI, and 1 PI/r. To be eligible for the analyses presented here, concurrent CD4⁺ T-cell counts and viral loads had to be available at the time of and at least 1 time after detection of triple-class virologic failure.

Statistical Analysis

We analyzed absolute CD4⁺ T-cell counts measured from the time of triple-class virologic failure onward. Counts were

analyzed by marginal linear regression, using generalized estimating equations with exchangeable correlation structure and robust standard errors taking into account repeated measures per individual. This approach differs slightly from our previous analysis [9], in which we studied ongoing changes in CD4⁺ T-cell counts. In addition to the linear term, we added a quadratic term for the CD4⁺ T-cell count obtained at detection of triple-class virologic failure, to account for the fact that increases will not be linear across all CD4⁺ T-cell counts but will likely be reduced at higher CD4⁺ T-cell counts (ie, a ceiling effect). In addition to CD4⁺ T-cell count, sex and HIV acquisition through contaminated needles (ie, injection drug use [IDU]) were used as fixed (baseline) covariables. Age, viral load, type of ART, and calendar year were introduced as time-updated covariables. Continuous variables were checked for linearity of associations. We grouped antiretroviral treatment into the following regimen types: NNRTI plus 2 NRTIs, PI/r plus 2 NRTIs, PI (unboosted) plus 2 NRTIs, ≥1 NNRTI plus ≥1 PI plus ≥1 NRTI, regimens containing a new class, other regimens, and no receipt of treatment. Fusion inhibitors, integrase inhibitors, and CCR5 coreceptor antagonists were considered new classes. We lagged treatment information by 1 month to reduce the risk of reverse causality effects. Results of the multivariable model were then used to predict CD4⁺ T-cell count changes from a fixed baseline value (eg, 300 cells/μL at triple-class virologic failure) at a specific time point after triple-class virologic failure (eg, 2 years), for different current viral levels and for the different regimen types. In sensitivity analyses, we used random-effects models instead of generalized estimating equations, and we also evaluated estimates without including the quadratic CD4⁺ T-cell count term.

We used Stata software, version 12.1/SE (StataCorp, College Station, TX), and SAS software, version 9.1, for statistical analyses.

RESULTS

There were 91 764 eligible persons from 24 cohorts who initiated ART, of whom 2722 experienced triple-class virologic failure. CD4⁺ T-cell count and viral load at the time of triple-class virologic failure and at ≥1 subsequent time point were available for 2424 individuals (89%). The characteristics of the selected persons are shown in Table 1. Compared with the 2424 analyzed people, the 298 excluded individuals had experienced triple-class virologic failure in more recent years (2007 vs 2005; $P < .001$), had received ART for a longer period at the time of triple-class virologic failure (5.1 vs 4.3 years; $P < .001$), and were more likely to be receiving regimens with an NNRTI (13% vs 11%) or a boosted PI (59% vs 52%; $P = .022$). The other characteristics did not differ significantly. The 2424 persons contributed 23 922 CD4⁺ T-cell count measurements over a total of 7117 person-years of follow-up after triple-class

Table 1. Characteristics of 2424 Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Subjects at the Time of Triple-Class Virological Failure (VF)

Characteristic	Value
Age, y	40 (34–45)
Female sex	792 (33)
Transmission category	
Heterosexual	1133 (47)
Men who have sex with men	700 (29)
Injection drug use	346 (14)
Other	245 (10)
CDC stage C disease	914 (38)
CD4 ⁺ T-cell count, cells/ μ L	
At time of starting ART ^a	173 (60–300)
At time of triple-class VF	270 (148–426)
HIV-1 RNA load, log ₁₀ copies/mL	
At time of starting ART ^b	5.0 (4.4–5.5)
At time of triple-class VF	4.0 (3.2–4.8)
HIV-1 RNA load never <500 copies/mL prior to triple-class VF	288 (12)
Year of cART initiation	2000 (1998–2001)
Duration of ART until triple-class VF, y	4.3 (2.7–6.2)
Type of regimen at time of triple-class VF	
NNRTI + 2 NRTI	258 (11)
PI/r + 2 NRTI	1269 (52)
≥ 1 NNRTI + ≥ 1 PI + ≥ 1 NRTI	384 (16)
Any new class	34 (1.4)
Other regimen	479 (20)
No. of drugs in regimen at time of triple-class VF	3 (3–4)

Data are no. (%) of subjects or median (interquartile range).

Abbreviations: ART, antiretroviral therapy; CDC, Centers for Disease Control and Prevention; cART, combination antiretroviral therapy; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor; PI/r, ritonavir-boosted protease inhibitor.

^a Available for 2031 individuals (84%).

^b Available for 1966 individuals (81%).

virologic failure. The proportion of follow-up time spent with CD4⁺ T-cell counts of <50, <200, <350, and <500 cells/ μ L was 7.1%, 28%, 54%, and 75%, respectively. Before 2004, the proportion of follow-up time spent with a CD4⁺ T-cell count of <200 cells/ μ L was 36%; from 2004–2007, 32%; and after 2007, 24%. For the time spent with viral loads <50 and <500 copies/mL, the proportions were 40% and 59%, respectively. The median number of CD4⁺ T-cell count measurements per person was 9 (interquartile range [IQR], 5–15), corresponding to a median frequency of 3.9 measurements/patient-year (IQR, 3.0–5.2). The median CD4⁺ T-cell count at the time of triple-class virologic failure was 270 cells/ μ L, with a significant increase over calendar time, from 226 cells/ μ L for those developing triple-class virologic failure in 2000 to 319 cells/ μ L for those developing triple-class virologic failure in 2009 ($P < .001$, by the nonparametric test for trend). The courses of CD4⁺




Figure 1. CD4⁺ T-cell counts for 2424 individuals from 2 years before until 2 years after triple-class virologic failure (VF). Error bars extend from the first to the third quartile.

T-cell counts before and after triple-class virologic failure, according to the calendar period in which triple-class virologic failure occurred, are shown in Figure 1. From 2 years prior to triple-class virologic failure until 2 years after triple-class virologic failure, there was a continuous increase in median CD4⁺ T-cell count for all periods, but the wide IQRs revealed substantial heterogeneity in CD4⁺ T-cell counts in the population. As these findings may have been affected by survivor bias (ie, people with very low CD4⁺ T-cell counts were more likely to die), we repeated the analysis with CD4⁺ T-cell counts set to 0 after death of the 182 persons who died. The resulting curves were virtually unchanged (data not shown).

Associations between CD4⁺ T-cell counts after triple-class virologic failure with various covariables are shown in Table 2. Univariable models (data not shown) yielded results very similar to those of bivariable models that adjusted for the linear and quadratic terms of CD4⁺ T-cell counts at triple-class virologic failure. Bivariable models showed a strong inverse linear association between CD4⁺ T-cell counts and viral load, resulting in a CD4⁺ T-cell count decrease of 48 cells/ μ L (95% CI, 45–51) per log₁₀ increase in HIV-1 RNA copies. In addition, older age and later calendar time were positively associated with higher CD4⁺ T-cell counts. Furthermore, compared with NNRTI-based regimens, treatments with a boosted PI or treatments including new drug classes were positively associated with CD4⁺ T-cell count. No receipt of treatment, however, was associated with a markedly lower CD4⁺ T-cell count (–64 cells/ μ L; 95% CI, –90 to –39). Of persons who received drugs from new classes during follow-up, 174 (7%) received a fusion inhibitor, 208 (9%) received an integrase inhibitor, and 26 (1%) received a CCR5 coreceptor antagonist. Associations with different regimens were only slightly affected when the model was adjusted for demographic variables and whether viral load had ever been suppressed

Table 2. Predictors of CD4⁺ T-Cell Counts Among Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Subjects After Triple-class Virological Failure (VF)

Characteristic	Average Difference in CD4 ⁺ T-Cell Count (95% CI) ^a					
	Bivariable Models	<i>P</i>	Multivariable Model 1	<i>P</i>	Multivariable Model 2	<i>P</i>
Female sex	-5.0 (-17 to 6.6)	.40	36 (21–52)	<.001	24 (12–37)	<.001
Age (per 10 y increase) ^b	109 (90–127)	<.001	98 (81–116)	<.001	59 (45–72)	<.001
HIV-1 RNA load never <500 copies/mL prior to triple-class VF	-12 (-29 to 5.3)	.18	-6.3 (-28 to 15)	.57	21 (2.7–38)	.024
HIV-1 acquisition via IDU	-1.4 (-18 to 15)	.87	7.5 (-10 to 25)	.41	9.3 (-6.4 to 25)	.25
HIV-1 RNA load (per log ₁₀ copies/mL) ^b	-48 (-51 to -45)	<.001	Not included		Not included	
HIV-1 RNA load, log ₁₀ copies/mL ^b						
<2.5	0 (Reference)		Not included		0 (Reference)	
2.5 to <3.5	-57 (-63 to -50)	<.001	...		-51 (-57 to -45)	<.001
3.5 to <4.5	-92 (-100 to -85)	<.001	...		-84 (-91 to -77)	<.001
4.5 to <5.5	-147 (-157 to -137)	<.001	...		-137 (-147 to -127)	<.001
≥5.5	-197 (-218 to -175)	<.001	...		-186 (-207 to -164)	<.001
ART ^c						
NNRTI + 2 NRTI	0 (Reference)		0 (Reference)		0 (Reference)	
PI/r + 2 NRTI	31 (12–50)	.001	22 (3.9–41)	.017	-3.8 (-19 to 12)	.64
Old 3 classes ^d	4.0 (-21 to 29)	.76	4.9 (-20 to 30)	.70	-9.5 (-31 to 12)	.38
Any new class ^e	61 (37–86)	<.001	39 (15–62)	.001	-20 (-41 to 0.51)	.056
Other regimens	16 (-2.4 to 35)	.088	7.4 (-10 to 25)	.42	-10 (-26 to 5.0)	.18
No ART	-64 (-90 to -39)	<.001	-69 (-93 to -44)	<.001	-34 (-56 to -12)	.002
Calendar time (per year) ^b	21 (18–24)	<.001	Not included		Not included	

Results are based on 2424 individuals with 23 922 CD4⁺ T-cell count measurements. Results from additional models also adjusted for calendar year are available in the Supplementary Materials.

Abbreviations: ART, antiretroviral therapy; CI, confidence interval; IDU, injection drug use; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor; PI/r, ritonavir-boosted protease inhibitor.

^a Bivariable models adjusted only for CD4⁺ T-cell count at triple-class VF (both linear and quadratic terms). Multivariable model 1 does not include current viral load and calendar year, whereas multivariable model 2 includes current viral load. *P* values are from marginal linear regression, using generalized estimating equations with exchangeable correlation structure and robust standard errors.

^b Variable updated with time.

^c Variable updated with time but lagged by 1 month.

^d At least 1 of each of NRTI, PI, and NNRTI.

^e At least 1 of fusion inhibitors, CCR5 coreceptor antagonists, or integrase inhibitors.

prior to triple-class virologic failure (Table 2). However, adjustment for the most recently measured viral load eliminated or even reversed the associations between regimen types and CD4⁺ T-cell count, suggesting that the differential effect of regimen types is primarily mediated through most recently measured viral load (Table 2). The increase of CD4⁺ T-cell count with calendar time was 21 cells/μL per year (95% CI, 18–24) in the bivariable model. This association was only marginally affected in adjusted analysis without current viral load (19 cells/μL per year [95% CI, 16–21]) and with current viral load (14 cells/μL per year [95% CI, 11–16]; Supplementary Table). Of note, all models had a significant negative quadratic term for CD4⁺ T-cell count at triple-class virologic failure, indicating a ceiling for CD4⁺ T-cell counts after triple-class virologic failure of 480–650 cells/μL. Figure 2 shows predicted CD4⁺ T-cell counts at 2 years after triple-class virologic failure for assumed starting values of 300 cells/μL at the

time of triple-class virologic failure. There was very little difference between the regimens once viral load was taken into account.

Without differentiating by regimen, the predicted CD4⁺ T-cell counts attained at viral levels of 2, 3, 4, 5, and 6 log₁₀ copies/mL were 386 (95% CI, 379–392), 342 (95% CI, 337–348), 299 (95% CI, 294–305), 256 (95% CI, 249–263), and 213 (95% CI, 204–222) cells/μL, respectively. Overall, decreasing CD4⁺ T-cell counts were seen at viral levels of >4.12 log₁₀ copies/mL (ie, 13 000 copies/mL), for which the predicted CD4⁺ T-cell count was 294 cells/μL (95% CI, 289–299; note that the upper boundary of the 95% CI did not include the starting value of 300 cells/μL).

The estimates remained virtually unchanged in sensitivity analyses with random-effects models instead of generalized estimating equations and in models that omitted the quadratic term for the CD4⁺ T-cell count.




Figure 2. Predicted CD4⁺ T-cell counts at 2 years after triple-class virologic failure for different levels of time-updated viral load and regimens. Information on regimens was also updated with time but lagged by 1 month. Results are from marginal linear regression using generalized estimating equations with exchangeable correlation structure and robust standard errors taking into account repeated measures per individual. The model was adjusted for linear and quadratic terms of CD4⁺ T-cell count at triple-class virologic failure, years since triple-class virologic failure, time-updated viral load and regimens, and interaction terms of the latter 2. Results are based on 2424 individuals with 23 922 CD4⁺ T-cell count measurements. Error bars show 95% confidence intervals of the predicted CD4⁺ T-cell counts. Results were very similar (<2 cells differences in predictions) when the model was also adjusted for sex, injection drug use, age, and whether viral load had ever been <500 copies/mL. Abbreviations: NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PI/r, ritonavir-boosted protease inhibitor.

DISCUSSION

We have shown that the current virus concentration in plasma is the single most important predictor of the current CD4⁺ T-cell count in 2424 people who started ART during or after 1998 and then experienced triple-class virologic failure. There is close to an inverse linear relationship between log₁₀ viral load and CD4⁺ T-cell count. These results confirm and extend the findings from our previous study of individuals with triple-class virologic failure, of whom most had started antiretroviral treatment with monotherapy or dual therapy, a situation less relevant to current practice than our analysis reported here [9]. The group with triple-class virologic failure we are studying here is likely to be heterogeneous and also includes people who have previous or ongoing issues involving treatment adherence. Of note, 12% of people in our study had not attained undetectable viral levels prior to the time of triple-class virologic failure. If adherence problems can be overcome before resistance has developed, the drugs should remain active, and

options have not been lost. However, it is often not easy to know in practice whether resistance in such cases is really absent, because minority variants harboring drug resistance may have emerged but are missed with routine genotypic assays [15]. Some individuals may also have been infected with HIV strains resistant to certain components of the initial regimen before baseline resistance tests were introduced and thus potentially may have received suboptimal treatments [16]. Unfortunately, we did not have information on adherence, drug concentrations, or resistance to antiretroviral drugs available for our analyses.

Although it is clear that complete viral suppression with a new fully active regimen is the optimal approach, the approximately linear inverse relationship between log₁₀ viral load and CD4⁺ T-cell count indicates that there are likely CD4⁺ T-cell count benefits of lowering viral load even by modest amounts that do not lead to undetectable viral levels. This may be important for patients with low CD4⁺ T-cell counts and few drug options. The superior effect of boosted PIs over unboosted PIs and NNRTIs, which we found in univariable and bivariable models, is consistent with results from our initial study [9] and from a large subsequent study from the EuroSIDA Study Group [17]. This effect was removed when current viral loads, which directly reflect the desired treatment effects, were included in the model. However, although the difference in CD4⁺ T-cell counts between regimens seemed to disappear after adjustment for viral load, the heterogeneity within the regimen categories may have concealed differences in immunologic response despite similar viral suppression of some of these regimens, as observed in clinical trials with treatment-naïve individuals [18, 19]. We used incremental models to demonstrate the effect of including new variables that are correlated with existing variables on the parameter estimates. For example, calendar time is correlated with the introduction of new drugs over time, and estimates of the latter are substantially altered when both variables are analyzed together.

The positive association of CD4⁺ T-cell count with age may be explained by better adherence among older people [13], but it also may be due to the correlation of time-updated age with calendar time and, thus, the increased availability of better drugs over time. In fact, the association with age disappeared in models that were also adjusted for calendar time.

It may be confusing that never having achieved an undetectable viral load prior to the triple-class virologic failure is positively associated with CD4⁺ T-cell counts in models including current viral load. A possible explanation could be that, once we condition on a given low current viral load, people who have not previously experienced viral suppression might tend to enjoy a higher CD4⁺ T-cell count increase, as is observed in the first few weeks of treatment. In other words, if a low viral load can be attained in persons who have not

previously suppressed the viral load, they will experience greater CD4⁺ T-cell count benefits, as CD4⁺ T-cell count increases are greater in those who have recently started ART.

Descriptive analyses showed that, on average, people have experienced triple-class virologic failure at higher average CD4⁺ T-cell counts in recent years, which can be explained by a trend toward earlier initiation of ART. Furthermore, the observation that CD4⁺ T-cell counts continue to increase after triple-class virologic failure may be related to the fact that new drugs, including those with novel targets, decrease viral load even in patients with several previous virological failures.

We used the definition of triple-class virologic failure that has been used in previous studies of our group [10, 11, 20]. As described by Lodwick et al [11], results were robust with regard to modifications of the definition.

Our study has several potential limitations. It could be challenged that we assumed a strong effect of viral load on CD4⁺ T-cell count, rather than a strong effect of CD4⁺ T-cell count on viral load. We acknowledge that there could be some confounding, such that the observed relationship is not entirely due to the causal effect of viral load on CD4⁺ T-cell count, but we think there is good reason to consider that the observation is mainly driven by this effect rather than by a causal effect of CD4⁺ T-cell count on viral load. This is supported, for example, by the observation that, in untreated patients, the viral load remains relatively stable over many years across a wide range of CD4⁺ T-cell counts [21]. Treatment strategies, availability of antiretroviral drugs, and methods of laboratory assessments may have differed somewhat between the collaborating cohorts. The cohorts in this collaboration cover most countries across Western Europe. Cohorts from France, the Netherlands and Switzerland include a majority of individuals on ART (>70%), the UK study includes close to 50% from the country. People from these countries represent 66% of patients enrolled in the present study. However, we cannot rule out the possibility that clinics participating in cohorts have a higher standard of care and a higher level of viral suppression than clinics that are not participating. In contrast to first-line treatments, ART regimens administered to individuals after they experience triple-class virologic failure are very heterogeneous. It was therefore not possible to include specific drugs or regimens in our analyses. In addition, we had to combine drugs from novel classes, which have quite different antiviral potencies, into a single group because small numbers of individuals were receiving these agents. Furthermore, we did not have information on coinfection with hepatitis C virus, which has been described by some studies [22] but not others [23] as potentially influencing recovery of the CD4⁺ T-cell count during ART.

In conclusion, we have identified a strong inverse linear relationship between log₁₀ viral load and CD4⁺ T-cell count in people with virologic failure of the original 3 drugs in the

modern ART era. Thus, any degree of viral suppression is likely to bring benefits in terms of CD4⁺ T-cell count and, hence, risk of clinical disease. In contrast, not receiving ART is clearly associated with lower CD4⁺ T-cell counts, although there may be some confounding in play, along with the causal effect of stopping, such as poor adherence, illicit drug use, alcohol abuse, or psychiatric problems. There are implications for patients with an unsuppressed viral load and a low CD4⁺ T-cell count. Although for individuals with a high CD4⁺ T-cell count it may be possible to wait until new active drugs are available, for those with a low CD4⁺ T-cell count it is important to use the regimen most likely to achieve maximal achievable viral suppression. We found that the current viral load is closely linked to the CD4⁺ T-cell count, suggesting a rapid benefit of viral load suppression. Therefore, for an individual who is not fully adherent, any increase in adherence is likely to provide immediate benefits in terms of reduced risk of clinical disease, unless the individual's virus is fully resistant to the actual regimen, which is unusual. In addition, we identified associations between use of drugs from specific classes and improved CD4⁺ T-cell counts, which were mediated by the differential effects of these regimens on viral load.

ANALYSIS AND WRITING COMMITTEE (PLATO II PROJECT TEAM)

All members of the PLATO II analysis and writing committee participated in discussions on the design of the study, the choice of statistical analyses and interpretation of the findings, and critically reviewed the manuscript. Dominique Costagliola, Bruno Ledergerber, Carlo Torti, Ard van Sighem, Daniel Podzamczar, Amanda Mocroft, Maria Dorrucchi, Bernard Masquelier, Andrea de Luca, Klaus Jansen, Stephane De Wit, Niels Obel, Gerd Fätkenheuer, Giota Touloumi, Cristina Mussini, Antonella Castagna, Cristoph Stephan, Federico García, Robert Zangerle, Xavier Duval, Santiago Perez-Hoyos, Laurence Meyer, Jade Ghosn, Céline Fabre-Colin, Jesper Kjaer, and Genevieve Chene contributed to data acquisition and management. Céline Fabre-Colin, Jesper Kjaer, and Jesper Garup provided administrative, technical, and material support. Bruno Ledergerber, Andrew Phillips, Dominique Costagliola, and Rebecca Lodwick were responsible for the study concept and design, have full access to the data set, performed all analyses, interpreted the data, and drafted the report.

Bruno Ledergerber (Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Switzerland), Dominique Costagliola (UPMC Univ Paris 06, UMR_S 943, and INSERM, UMR_S 943, Paris, France), Rebecca Lodwick (HIV Epidemiology and Biostatistics Group, Research Department of Infection and Population Health, Institute of Epidemiology and Health Care, University College London, United Kingdom), Carlo Torti (Institute for

Infectious and Tropical Diseases, University of Brescia, and Unit of Infectious Diseases, University "Magna Graecia", Catanzaro, Italy), Ard van Sighem (Stichting HIV Monitoring, Amsterdam, the Netherlands), Daniel Podzamczar (HIV Unit, Infectious Disease Service, Hospital Universitari de Bellvitge, L'Hospitalet, Barcelona, Spain), Amanda Mocroft (HIV Epidemiology and Biostatistics Group, Research Department of Infection and Population Health, Institute of Epidemiology and Health Care, University College London, United Kingdom), Maria Dorrucchi (Department of Infectious, Parasitic, and Immunomediated Diseases, Istituto Superiore di Sanità, Rome, Italy), Bernard Masquelier (Univ Bordeaux, Microbiologie fondamentale et Pathogénicité, UMR 5234, and Laboratoire de Virologie, CHU de Bordeaux, Bordeaux, France), Huldrych F. Günthard (Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Switzerland), Andrea de Luca (University Division of Infectious Diseases, Siena University Hospital, and Institute of Clinical Infectious Diseases, Università Cattolica del Sacro Cuore, Roma, Italy), Claudia Michalik (Kompetenznetz HIV/AIDS, University Bochum, Germany), Stephane De Wit (Department of Infectious Diseases, St Pierre University Hospital, Brussels, Belgium), Niels Obel (Department of Infectious Diseases, Copenhagen University Hospital, Denmark), Gerd Fätkenheuer (Department of Internal Medicine I, University of Cologne, Germany), George Chrysos (Infectious Diseases Unit, TZANEIO General Hospital of Piraeus, Greece), Cristina Mussini (Clinica delle Malattie Infettive, Policlinico, Modena, Italy), Antonella Castagna (Department of Infectious and Tropical Diseases, San Raffaele Scientific Institute, Milano, Italy), Cristoph Stephan (Johann Wolfgang Goethe-University Hospital, Medical Center/Infectious Diseases Unit, Frankfurt am Main, Germany), Federico García (Microbiology Department, Hospital Universitario San Cecilio, Granada, Spain), Robert Zangerle (Department of Dermatology and Venereology, Innsbruck Medical School, Austria), Xavier Duval (Univ Paris Diderot, Sorbonne Paris Cité, INSERM, U738, CIC 007, and AP-HP, Hôpital Bichat Claude Bernard, CIC, Paris, France), Santiago Perez-Hoyos (Vall d'Hebrón Institut de Recerca. Universitat Autònoma de Barcelona, Spain), Laurence Meyer (Inserm, CESP U1018, Univ Paris Sud, and AP-HP, Hopital Bicêtre, Epidemiology and Public Health Service, Le Kremlin Bicêtre, France), Jade Ghosn (Service de Médecine Interne et Maladies Infectieuses, CHU Bicêtre, France), Céline Fabre-Colin (Univ Bordeaux, ISPED, and INSERM, Centre INSERM U897, Bordeaux, France), Jesper Kjaer (Copenhagen HIV Programme, University of Copenhagen, Denmark), Jesper Grarup (Copenhagen HIV Programme, University of Copenhagen, Denmark), Genevieve Chêne (Univ Bordeaux, ISPED, INSERM, Centre INSERM U897, and CHU de Bordeaux, Pole de sante publique, Bordeaux, France), and Andrew Phillips (HIV

Epidemiology and Biostatistics Group, Research Department of Infection and Population Health, Institute of Epidemiology and Health Care, University College London, United Kingdom).

Supplementary Data

Supplementary materials are available at *The Journal of Infectious Diseases* online (<http://jid.oxfordjournals.org/>). Supplementary materials consist of data provided by the author that are published to benefit the reader. The posted materials are not copyedited. The contents of all supplementary data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.

Notes

Financial support. This work was supported by the Medical Research Council (award G0700832 to the PLATO II project); the Agence Nationale de Recherches sur le SIDA et les Hépatites Virales, France (to the COHERE study); the HIV Monitoring Foundation, the Netherlands (to the COHERE study); the Augustinus Foundation, Denmark (to the COHERE study); and the European Union Seventh Framework Programme (FP7/2007–2013 to the COHERE study, under EuroCoord grant agreement 260694). A list of the funders of the participating cohorts can be found on the regional coordinating center Web sites (available at: <http://www.cohere.org>).

Potential conflict of interest. All authors: No reported conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. *JAMA* **2010**; 304:321–33.
2. Mocroft A, Ledergerber B, Viard JP, et al. Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group. *J Infect Dis* **2004**; 190:1947–56.
3. Lohse N, Obel N, Kronborg G, et al. Declining risk of triple-class antiretroviral drug failure in Danish HIV-infected individuals. *AIDS* **2005**; 19:815–22.
4. Gardner EM, Burman WJ, Steiner JF, Anderson PL, Bangsberg DR. Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. *AIDS* **2009**; 23:1035–46.
5. Sabin CA, Hill T, Lampe F, et al. Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study. *BMJ* **2005**; 330:695.
6. Lohse N, Jorgensen LB, Kronborg G, et al. Genotypic drug resistance and long-term mortality in patients with triple-class antiretroviral drug failure. *Antivir Ther* **2007**; 12:909–17.
7. Fagard C, Colin C, Charpentier C, et al. Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial. *J Acquir Immune Defic Syndr* **2012**; 59:489–93.
8. Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. *Clin Infect Dis* **2009**; 49:1441–9.
9. Ledergerber B, Lundgren JD, Walker AS, et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected

- individuals with virological failure to all three antiretroviral-drug classes. *Lancet* **2004**; 364:51–62.
10. The Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). Trends over calendar time in virological and clinical outcomes in HIV-1 infected people with virologic failure of drugs from the three original antiretroviral drug classes: an observational cohort study. *Lancet Infect Dis* **2011**; 12:119–27.
 11. The Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. *Arch Intern Med* **2010**; 170:410–9.
 12. The Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe. *J Acquir Immune Defic Syndr* **2012**; 59:294–9.
 13. Sabin C, Smith CJ, d'Arminio Monforte A, et al. Response to combination antiretroviral therapy: variation by age. *AIDS* **2008**; 22:1463–73.
 14. Kjaer J, Ledergerber B. HIV cohort collaborations: proposal for harmonization of data exchange. *Antivir Ther* **2004**; 9:631–3.
 15. Li JZ, Paredes R, Ribaud HJ, et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. *JAMA* **2011**; 305:1327–35.
 16. Wittkop L, Günthard HF, de Wolf F, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. *Lancet Infect Dis* **2011**; 11:363–71.
 17. Mocroft A, Phillips AN, Ledergerber B, et al. Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy. *Antivir Ther* **2010**; 15:563–70.
 18. Cooper DA, Heera J, Goodrich J, et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naïve subjects with CCR5-tropic HIV-1 infection. *J Infect Dis* **2010**; 201:803–13.
 19. Rockstroh JK, Lennox JL, Dejesus E, et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naïve human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. *Clin Infect Dis* **2011**; 53:807–16.
 20. The Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). Risk of triple-class virological failure in children with HIV: a retrospective cohort study. *Lancet* **2011**; 377:1580–7.
 21. Pantaleo G, Graziosi C, Fauci AS. New concepts in the immunopathogenesis of human immunodeficiency virus infection. *N Engl J Med* **1993**; 328:327–35.
 22. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. *Lancet* **2000**; 356:1800–5.
 23. Rockstroh JK, Mocroft A, Soriano V, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. *J Infect Dis* **2005**; 192:992–1002.

APPENDIX

PLATO II Project Team

Anne Audelin (Danish HIV Cohort), Antonella Castagna (San Raffaele), Dominique Costagliola (ANRS CO4 FHDH), Alessandro Cozzi-Lepri (ICONA), Andrea De Luca (ICONA),

Stephane De Wit (St Pierre Cohort), Frank de Wolf (ATHENA), Maria Dorrucci (CASCADE), Xavier Duval (ANRS CO8 COPILOTE), Gerd Fätkenheuer (Cologne Bonn), Federico García (CoRIS), Jade Ghosn (ANRS CO6 PRIMO), Huldrych Günthard (SHCS), Klaus Jansen (KOMPNET), Ali Judd (CHIPS), Bruno Ledergerber (SHCS), Sergio Lo Caputo (Italian Master Cohort), Rebecca Lodwick (statistician), Bernard Masquelier (ANRS CO3 AQUITAINE), Laurence Meyer (ANRS CO2 SEROCO), Amanda Mocroft (EuroSIDA), Cristina Mussini (Modena Cohort), Antoni Noguera-Julian (CORISPE-cat), Niels Obel (Danish HIV Cohort), Dimitrios Paraskevis (AMACS), Roger Paredes (EuroSIDA), Santiago Pérez-Hoyos (GEMEShaemo), Andrew Phillips (PLATO II project leader; UK HIV Drug Resistance Database/UK CHIC), Deenan Pillay (UK HIV Drug Resistance Database/UK CHIC), Daniel Podzamczar (PISCIS), José T. Ramos (Madrid Cohort), Christoph Stephan (Frankfurt HIV Cohort), Pat A. Tookey (NSHPC), Carlo Torti (Italian Master Cohort), Giota Touloumi (AMACS), Ard van Sighem (ATHENA), Josiane Warszawski (ANRS CO1 EPF), and Robert Zangerle (AHIVCOS).

COHERE Steering Committee

Steering Committee

Contributing cohorts: Robert Zangerle (AHIVCOS), Giota Touloumi (AMACS), Josiane Warszawski (ANRS CO1 EPF/ANRS CO11 OBSERVATOIRE EPF), Laurence Meyer (ANRS CO2 SEROCO), François Dabis (ANRS CO3 AQUITAINE), Murielle Mary Krause (ANRS CO4 FHDH), Jade Ghosn (ANRS CO6 PRIMO), Catherine Lepout (ANRS CO8 COPILOTE), Frank de Wolf (ATHENA), Peter Reiss (ATHENA), Maria Prins (CASCADE), Heiner Bucher (CASCADE), Caroline Sabin (CHIC), Diana Gibb (CHIPS), Gerd Fätkenheuer (Cologne Bonn), Julia Del Amo (CoRIS), Niels Obel (Danish HIV Cohort), Claire Thorne (ECS), Amanda Mocroft (EuroSIDA), Ole Kirk (EuroSIDA), Christoph Stephan (Frankfurt), Santiago Pérez-Hoyos (GEMES-Haemo), Antoni Noguera-Julian (NENEXP and CORISPE-cat), Andrea Antinori (ICC), Antonella d'Arminio Monforte (ICONA), Norbert Brockmeyer (KOMPNET), José Ramos (Madrid Cohort), Manuel Battegay (MoCHIV), Andri Rauch (SHCS), Cristina Mussini (Modena Cohort), Pat Tookey (NSHPC), Jordi Casabona (PISCIS), Jose M. Miró (PISCIS), Antonella Castagna (San Raffaele), Stephane de Wit (St. Pierre Cohort), Tessa Goetghebuer (St Pierre Paediatric Cohort), Carlo Torti (Italian Master Cohort), Ramon Teira (VACH), Myriam Garrido (VACH), and David Haerry (European AIDS Treatment Group).

Executive Committee

Ian Weller (Chair, University College London), Jordi Casabona (PISCIS), Dominique Costagliola (FHDH), Antonella d'Arminio-Monforte (ICONA), Manuel Battegay (MoCHIV),

Maria Prins (CASCADE), Frank de Wolf (ATHENA), Jesper Grarup (head, Copenhagen Regional Coordinating Centre), and Genevieve Chene (head, Bordeaux Regional Coordinating Centre).

Regional Coordinating Centers

Bordeaux RCC cohorts: Céline Colin, Christine Schwimmer, and Guillaume Touzeau; Copenhagen RCC cohorts: Jesper Kjaer and Maria Campbell.

Project Leaders and Statistical Analysis

Julia Bohlius, Vincent Bouteloup, Heiner Bucher, Alessandro Cozzi-Lepri, François Dabis, Antonella d'Arminio Monforte, Frank de Wolf, Maria Dorrucchi, Matthias Egger, Frederik Engsig, Hansjakob Furrer, Ole Kirk, Olivier Lambotte, Charlotte Lewden, Rebecca Lodwick, Sophie Matheron, Laurence Meyer, Jose Miro, Amanda Mocroft, Niels Obel, Roger Paredes, Andrew Phillips, Massimo Puoti, Joanne Reekie, Caroline Sabin, Alexandra Scherrer, Colette Smit, Jonathan Sterne, Rodolphe Thiebaut, Claire Thorne, Carlo Torti, Viktor von Wyl, and Linda Wittkop.